Hi, Rafael Fonseca here, I am frequently asked what constitutes stable disease in the context of myeloma. This has different meaning whether the patient is in a relapsed or refractory state versus a patient who is receiving therapy for front-line myeloma. But it is essentially any patient who does not meet criteria for the aforementioned categories. I suspect in the future, versions of this response criteria, we might introduce minor response, that has been shown to have clinical benefit in the setting of relapsed and refractory myeloma. But as it stands right now, as we look at patients who have no evidence of any of the aforementioned responses.
Reviewed on January 17, 2017 for clinical relevance.